Pailin Biology: The investment casting volume in 2025 is expected to increase by over 20% compared to the previous year.

Pailin Biological expressed on the interactive platform that the company has now obtained approvals from over 10 county-level and over 5 city-level authorities. In 2025, the company will focus on expanding new plasma stations and strive to achieve a breakthrough in new plasma stations. In addition, the company stated that the year-on-year decline in operating performance in the first quarter of 2025 was mainly due to the impact of the suspension of production capacity expansion of its subsidiary company, Paisifei Ke, Phase II. However, after the expansion of production capacity, the estimated plasma injection volume in 2025 will exceed 1400 tons, with a year-on-year increase in plasma injection volume of over 20%. The company's target profit growth rate will be maintained at more than double digits.